Sonnet BioTherapeutics, Inc. (NASDAQ:SONN) | WebDisclosure

Basculer en Français

8295	Companies
114850	Keywords
55292	Articles
62440	Press releases

Headlines Articles Press releases Sonnet BioTherapeutics, Inc.

Home
Companies
Sonnet BioTherapeutics, Inc.

BRIEF

published on 05/06/2024 at 13:05, 6 months 14 days ago

Sonnet BioTherapeutics to Present at EF Hutton Annual Global Conference

Biopharmaceuticals Sonnet BioTherapeutics Investor Meetings EF Hutton Conference Innovative Drugs
PRESS RELEASE

published on 05/06/2024 at 13:00, 6 months 14 days ago

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
Sonnet BioTherapeutics Holdings, Inc. to participate in EF Hutton Global Conference on May 15, 2024, presenting innovative biologic drugs. Learn about their oncology-focused technology

Sonnet BioTherapeutics Holdings Inc. EF Hutton Annual Global Conference Innovative Biologic Drugs Oncology-focused Technology Investment Bank
BRIEF

published on 03/19/2024 at 12:35, 8 months 1 day ago

Sonnet BioTherapeutics présentera la recherche SON-080 à l'AACR 2024

Sonnet BioTherapeutics Produits Biopharmaceutiques FILS-080 CIPN RCAA 2024
BRIEF

published on 03/19/2024 at 12:35, 8 months 1 day ago

Sonnet BioTherapeutics to Showcase SON-080 Research at AACR 2024

Biopharmaceuticals Sonnet BioTherapeutics SON-080 CIPN AACR 2024
PRESS RELEASE

published on 03/19/2024 at 12:30, 8 months 1 day ago

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
Sonnet BioTherapeutics to present preclinical data on SON-080 for neuropathies at AACR Annual Meeting 2024. The study focuses on safety and clinical plans using recombinant human Interleukin-6

Biopharmaceutical Sonnet BioTherapeutics SON-080 AACR Annual Meeting Interleukin-6
BRIEF

published on 03/11/2024 at 12:35, 8 months 9 days ago

Sonnet BioTherapeutics passe à la phase 2 de son essai clinique pour le traitement de la neuropathie

Sonnet BioTherapeutics FILS-080 Essai Clinique De Phase 1b/2a Neuropathie Périphérique Induite Par La Chimiothérapie Neuropathie Périphérique Diabétique
BRIEF

published on 03/11/2024 at 12:35, 8 months 9 days ago

Sonnet BioTherapeutics Moves Toward Phase 2 in Clinical Trial for Neuropathy Treatment

Sonnet BioTherapeutics SON-080 Phase 1b/2a Clinical Trial Chemotherapy-Induced Peripheral Neuropathy Diabetic Peripheral Neuropathy
PRESS RELEASE

published on 03/11/2024 at 12:30, 8 months 9 days ago

Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
Sonnet BioTherapeutics successfully completes Phase 1b trial of SON-080 with positive safety profile, paving the way for Phase 2 trial in Diabetic Peripheral Neuropathy (DPN) after potential partnership

Sonnet BioTherapeutics SON-080 Diabetic Peripheral Neuropathy Phase 1b Trial DSMB
BRIEF

published on 02/29/2024 at 22:10, 8 months 20 days ago

Sonnet BioTherapeutics annonce un essai de phase I sûr et tolérable pour SON-1010 chez des volontaires en bonne santé

Immunothérapie Sonnet BioTherapeutics FILS-1010 Recherche Contre Le Cancer Essai De Phase I
BRIEF

published on 02/29/2024 at 22:10, 8 months 20 days ago

Sonnet BioTherapeutics Reports a Safe and Tolerable Phase I Trial for SON-1010 in Healthy Volunteers

Cancer Research Immunotherapy Sonnet BioTherapeutics SON-1010 Phase I Trial

Accesswire

Published on 11/21/2024 at 11:30, 19 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 1 hour 46 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 1 hour 49 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 2 hours 49 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 11 hours 14 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 11:30, 19 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 11:01, 48 minutes ago

Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 11:00, 49 minutes ago

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
Published on 11/21/2024 at 10:56, 52 minutes ago

ABO Energy closes sale for two Battery Projects in South Africa
Published on 11/21/2024 at 10:30, 1 hour 19 minutes ago

MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024

Les Echos

Published on 11/21/2024 at 06:58, 4 hours 51 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 51 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 4 hours 51 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 15 hours 41 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 16 hours 29 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE